Investors Urged to Act: Inovio Pharmaceuticals Class Action Deadline Approaching in 2026

Inovio Pharmaceuticals Class Action: Important Deadline Approaching

Investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) are reminded of a crucial upcoming deadline concerning a federal securities class action lawsuit. Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims against Inovio Pharmaceuticals, emphasizing the necessity for affected investors to be aware of their rights and to take action.

Key Dates and Firm Overview

The deadline to seek the role of lead plaintiff in this lawsuit is set for April 7, 2026. A lead plaintiff is generally a member of the class action who has a significant financial interest in the case in question and who guides the litigation process. To be eligible, individuals must have purchased or acquired Inovio securities between October 10, 2023, and December 26, 2025. Anyone who fits this description is encouraged to contact Josh Wilson, a Senior Partner at Faruqi & Faruqi, directly for legal counsel regarding their options.

Faruqi & Faruqi is recognized for recovery efforts totaling hundreds of millions of dollars for investors since its inception in 1995. With offices in New York, Pennsylvania, California, and Georgia, the firm’s dedication to protecting investors is evident through its comprehensive services and legal support in such cases.

Allegations Against Inovio Pharmaceuticals

The allegations central to the lawsuit focus on claims that Inovio and its executives made misleading statements regarding the company’s performance and the regulatory prospects of its product, INO-3107. Specifically, it has been suggested that:
1. There were deficiencies in the manufacturing process for the CELLECTRA device crucial to the drug’s delivery.
2. The prospects for obtaining FDA approval for INO-3107 were overestimated, contributing to a false impression among investors.
3. The company failed to provide adequate information to endorse its application for accelerated approval of INO-3107.

These allegations were underscored when the U.S. Food and Drug Administration (FDA) announced on December 29, 2025, that it had accepted Inovio’s Biologics License Application for INO-3107. However, the FDA’s statement indicated that the sufficient information was lacking to support eligibility for accelerated path approval, prompting a notable drop in Inovio's stock price by 24.45%.

Investor Rights and Legal Support

As an investor affected by these events, participating in the class action could allow for the recovery of losses incurred during the specified period. If you believe you have such claims, you can seek to serve as the lead plaintiff or simply remain a class member, with the understanding that your ability to recover will not diminish regardless of your active participation.

Faruqi & Faruqi also extends its invitation to any individuals with additional information on the company’s practices to reach out, especially whistleblowers and former employees. Confidentiality is assured throughout the communication process.

For further information on the Inovio Pharmaceuticals class action, individuals can visit Faruqi & Faruqi’s dedicated page or get in touch with Mr. Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Keeping abreast of developments regarding this case and the rights of investors is vital as the deadline approaches.

Conclusion

In closing, investors in Inovio Pharmaceuticals are facing a crucial time as they consider their next steps regarding the pending class action lawsuit. With the legal landscape ever-changing, being proactive and informed is essential for securing rights and potential recovery in this matter. Don’t hesitate to reach out for guidance and assistance in navigating this complicated yet important situation.